Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases

Joint Bone Spine. 2015 Oct;82 Suppl 1:eS17-29. doi: 10.1016/S1297-319X(15)30004-X.

Abstract

A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described.

Keywords: Anakinra; Anti-IL-1β therapy; Canakinumab; Gouty arthritis; Tophaceous gout.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Gouty / drug therapy*
  • Chronic Disease
  • Colchicine / therapeutic use
  • Comorbidity
  • Febuxostat / therapeutic use
  • Gout Suppressants / therapeutic use*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Interleukin-1 / antagonists & inhibitors*
  • Male
  • Patient Selection*
  • Prednisolone / therapeutic use
  • Recurrence

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Gout Suppressants
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Febuxostat
  • canakinumab
  • Prednisolone
  • Colchicine